Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Industries is positioned for substantial growth, with projected sales for Ajovy and Uzedy expected to increase significantly, by 17% and 45% year-over-year, respectively, contributing to a diversified revenue stream. The company is anticipated to achieve an uplift in EBITDA margins through a strategic shift to a higher-value product base, along with ongoing growth in cash flows anticipated beyond 2027. Additionally, the strong performance of Austedo with US sales reaching $725 million in 4Q25 showcases the potential for further market share gains and pricing improvements, indicating a positive trajectory for the company's financial health.

Bears say

Teva Pharmaceutical Industries is facing a challenging outlook primarily due to expected revenue declines in 1Q26 and 4Q26, attributed to inventory patterns and pricing pressures related to the implementation of the Inflation Reduction Act (IRA). The company’s generics revenues missed estimates by 3% in 4Q25, reflecting an 11% year-over-year decline in US total prescriptions, which signals ongoing demand weakness in this segment. Additionally, ongoing risks include regulatory uncertainties, litigation, and concerns regarding the successful execution of their pharmaceutical pipeline, all of which threaten to undermine Teva's financial stability and growth trajectory.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.